Bariatric surgery

GLP-1 medications improved testosterone levels, sperm count, and sperm morphology in men after 24 weeks, according to a study led by Dr. Pratibha Natesh. However, experts caution more research is needed before prescribing these drugs for male infertility, noting potential risks from sudden weight loss and metabolic changes.

Participants with obesity achieved weight loss comparable to bariatric surgery and showed improvements in two obesity-related conditions while taking a once-weekly investigational triple hormone receptor agonist. The treatment is described as a novel approach for managing obesity.

Eli Lilly's obesity drug retatrutide demonstrated weight loss comparable to bariatric surgery in Phase 3 trials, with patients losing up to 28.3% of body weight after 80 weeks. However, the treatment showed concerning side effects with 11% discontinuation rates on the highest dose, significantly higher than competing drugs like Wegovy and Zepbound.

Experts warn that the widespread use of GLP-1 drugs like Ozempic and Wegovy may lead to an increase in divorces due to weight loss altering relationship dynamics. Studies suggest weight loss from these medications could create tension in marriages, with historical data from bariatric surgery patients showing a higher divorce rate among those who lost significant weight.

Weight loss drugs and bariatric surgery both reduce fat and cause modest muscle loss, altering body composition. While these treatments improve health, they involve trade-offs that impact mortality risk due to muscle's protective role.